Skip to main content
Solventum Cautions Investors Regarding TRC Capital's "Mini-Tender Offer"

ST. PAUL, Minn., June 7, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV) has been notified that TRC Capital Investment Corporation ("TRC") made an unsolicited "mini-tender offer" to purchase up to 2,000,000 shares of the company's common stock at $59.15 per share and decreased the offer price on June 6, 2024, to $55.00 per share. The closing stock price of Solventum's common stock on June 6, 2024 was $55.05.

As of the date of this press release, Solventum expresses no opinion and is neutral toward TRC's tender offer but cautions stockholders to monitor the trading price of the Solventum stock and any amendment to the offer price and to review the terms and conditions to the tender offer carefully. There is no guarantee the conditions of the offer will be satisfied.

Solventum stockholders who have already tendered their shares may withdraw them at any time by providing notice in the manner described in the TRC offering documents prior to the expiration of the offer, which is currently scheduled for 11:59 p.m., New York City time, on June 20, 2024, unless extended.

Solventum does not endorse TRC's unsolicited mini-tender offer. Solventum is not affiliated or associated in any way with TRC, its mini-tender offer, or its mini-tender offer documents.

TRC's mini-tender offer is not subject to many of the disclosure and procedural requirements of Securities and Exchange Commission (SEC) rules that are designed to protect investors. TRC has made similar unsolicited mini-tender offers for stock of other public companies. The SEC has cautioned investors about mini-tender offers, providing guidance to investors at http://www.sec.gov/investor/pubs/minitend.htm. Mini-tender offers seek to acquire not more than 5 percent of a company's outstanding shares, thereby avoiding many disclosure and procedural requirements of the SEC that are designed to protect investors.

Solventum urges stockholders to obtain current market quotations for their shares of stock, to consult their broker or financial advisor, and to exercise caution with respect to TRC's offer. Solventum requests that a copy of this news release be included with all distributions of materials relating to TRC's mini-tender offer related to Solventum's stock.

About Solventum
At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.

SOURCE Solventum

For further information: Solventum Investor Contact, Kevin Moran, investors@solventum.com; Solventum Media Contact, Michele Rest, news@solventum.com
Contact Investor Relations

These contacts are intended only for shareholders. If you are not a shareholder, please call 1-855-423-6725 (1-855-HC FOR ALL).

General inquiries:
investors@solventum.com

Contact us

Transfer agent contact information:

EQ Shareowner Services
P.O. Box 64854
St. Paul, MN 55164-0854
Toll Free: 1-888-666-0140   
Tel: 1-651-450-4064 (outside the United States)

An automated voice response system is available 24 hours a day, 7 days a week. Customer service representatives are available from 7:00 a.m. to 7:00 p.m., Central Standard Time, Monday through Friday.

Account information
https://www.shareowneronline.com